Core Viewpoint - The article emphasizes the importance of long-term investment strategies, particularly in growth stocks, as a means to navigate market volatility and achieve sustainable returns over time [1][2][5]. Investment Philosophy - The investment philosophy centers on the belief that true long-term returns come from companies that create value and possess core competitiveness, rather than from fleeting market trends [2][10]. - The approach involves low turnover rates and deep research, focusing on long-term tracking of companies rather than short-term performance metrics [2][11]. Performance Metrics - The Morgan Emerging Power Fund, managed by Du Meng since 2011, has achieved a total return of 796.77% and an annualized return of 16.52% as of November 12 [6]. - The Morgan China Advantage Fund, managed since 2019, has an annualized return of 19.13% and a cumulative total return of 1513.25%, marking it as one of the few funds to achieve a "15x base" since inception [6]. Long-Term Investment Strategy - Du Meng's strategy is characterized by a focus on long-term growth, emphasizing that the value realization of growth stocks is a gradual process requiring time [5][10]. - The investment framework includes a systematic approach to managing positions based on industry trends and company fundamentals, avoiding concentration risks [7][14]. Market Trends and Future Outlook - Du Meng remains optimistic about sectors such as renewable energy, AI, and pharmaceuticals, identifying them as structural opportunities for growth [9][15]. - The investment strategy is designed to withstand market fluctuations by focusing on the essence of industries and maintaining a long-term perspective [8][15]. Risk Management - Effective risk management is achieved through thorough research, ensuring investments are in fundamentally sound companies, and maintaining a disciplined approach to valuation [14][15]. - The strategy includes a dynamic allocation of positions based on the certainty and potential of individual stocks, enhancing the resilience of the overall portfolio [7][14].

Core Viewpoint - The article discusses the current state of the A-share market, highlighting the potential for continued investment opportunities, particularly in sectors like artificial intelligence, engineering machinery, chemicals, power batteries, and non-ferrous metals, despite the market's recovery being seen as a mere correction after previous declines [2][4]. Market Overview - The A-share market has reached 4000 points for the first time in ten years, with many investors achieving good returns this year [1]. - The overall market valuation remains reasonable and potentially undervalued, indicating room for further recovery as policies take effect and the economy rebounds [2]. Investment Focus Areas - The focus remains on transformative opportunities brought by AI, with ongoing tracking for more investment prospects [2]. - Other sectors of interest include engineering machinery, chemicals, power batteries, and non-ferrous metals, with traditional industries also showing potential [2]. Stock Selection Strategy - The strategy emphasizes selecting growth stocks, particularly those with stable earnings growth despite significant past declines, which may yield excess returns as performance materializes [4]. - The investment approach will prioritize sectors benefiting from economic transformation and consumer spending, as disposable income continues to rise [4]. Economic and Market Outlook - The outlook for the fourth quarter suggests that market opportunities may outweigh risks, with a focus on stock selection as the primary strategy [4]. - Factors such as potential interest rate cuts by the Federal Reserve, domestic liquidity easing, and supportive policies are expected to benefit the overall stock market [6]. Sector-Specific Insights - AI is highlighted as a key area for growth, with expectations for significant advancements in commercialization and applications in various fields [6]. - The lithium battery sector is anticipated to see increased demand, particularly from electric vehicles and energy storage, with a positive outlook for the second half of the year [6]. - Non-ferrous metals, particularly copper and gold, are expected to maintain strong demand and profitability due to favorable supply-demand dynamics [8]. Consumer Trends - The article notes a shift in consumer behavior among younger generations, leading to increased spending and the emergence of new consumption patterns, which could benefit specific sectors [17].

Core Insights - The article highlights the significant reforms in China's public fund industry, driven by the China Securities Regulatory Commission's action plan aimed at high-quality development, focusing on fiduciary responsibility and encompassing governance, product innovation, investment operations, and assessment mechanisms [1] - Morgan Asset Management (China) has successfully localized its operations, achieving a non-monetary public fund management scale of 133 billion yuan by Q3 2025, doubling its size in two years and improving its industry ranking by 20 positions, reflecting strong market recognition of its investment management capabilities [1] - The company emphasizes a long-term investment philosophy and has established a robust research-driven culture, which is crucial for generating sustainable alpha for clients [2][6] Company Strategy - Morgan Asset Management (China) has adopted a clear investment research structure, focusing on active management as its core competency, with teams dedicated to growth, balanced growth, and value investments, targeting various risk-return profiles [3] - The firm has identified key investment opportunities in artificial intelligence, leading Chinese manufacturers, and dividend assets, leveraging a dual driver of valuation recovery and earnings growth for structural market opportunities in 2025 [4] - The company has built a systematic talent development mechanism, nurturing fund managers with long-term commitment, evidenced by managers like Du Meng and Li Bo, who have delivered substantial returns over extended periods [4][5] Research and Analysis - Morgan Asset Management promotes a "research compounding" approach, emphasizing the importance of continuous research investment to enhance decision-making quality [6] - The firm has a global research team of 500 analysts, conducting extensive field research and maintaining high-frequency interactions with global teams to integrate local insights with global perspectives [6][7] - A unified research language and framework have been established to facilitate efficient resource sharing and collaboration across regions, enhancing the overall research quality [7] ETF Business Development - Morgan Asset Management has differentiated its ETF offerings by combining active management advantages, becoming the second-largest active ETF issuer globally and leading in net inflows since 2025 [8] - The company has launched 11 ETFs in China, focusing on investor experience and innovative features like quarterly mandatory dividends, catering to various investment strategies [8] - The firm continues to enhance its ETF business by providing localized market insights and strategies through reports and seminars, aiming to support index investors effectively [9] Future Outlook - The asset management industry is expected to increasingly favor long-termism, professional capabilities, and ecosystem collaboration, with Morgan Asset Management committed to refining its practices in investment management, product innovation, and client service [10]

Group 1 - The latest performance rankings of actively managed equity funds show that the average returns for actively managed stock and mixed funds are 35.5% and 32.4% respectively, outperforming stock ETFs at 31% [1] - The "Double Ten Funds," which have been established for over ten years and have an annualized return exceeding 10%, are gaining attention from long-term investors, with only about 8% of over 5000 stock and mixed funds meeting this criterion [1] - The "Double Ten Funds" are considered a benchmark in the fund industry, reflecting systematic advantages in team stability, investment discipline, and research capabilities of fund managers [1] Group 2 - The China Securities Regulatory Commission's recent action plan emphasizes that fund managers' assessments should focus on returns over three years, with a weight of no less than 80%, which is expected to promote long-term investment strategies among fund managers [2] - Morgan Fund has demonstrated strong long-term performance, with eight of its products meeting the "Double Ten" standard, showcasing resilience across multiple market cycles [2] - The Morgan Emerging Power Fund, managed by veteran Du Meng, has an annualized return exceeding 16% and has successfully captured investment opportunities in the electric vehicle and AI sectors [2] Group 3 - Looking ahead, the market is expected to balance between technology growth and economic recovery, with a positive mid-term outlook driven by upcoming policy meetings and global liquidity favoring emerging markets [3] - Future investment focus will be on clear industry trends, independent economic conditions, and policy support [3]

Core Viewpoint - The article emphasizes the importance of active management and deep research in asset management, highlighting Morgan Asset Management's commitment to these principles over the past two decades, which has led to sustained performance and investor trust [2][3]. Group 1: Active Management and Investment Culture - Morgan Asset Management has built a strong investment culture and a stable research team, focusing on long-term value rather than short-term gains, which has resulted in consistent performance [2][3]. - The average tenure of stock fund managers at Morgan Asset Management is approximately 20 years, with many research analysts having over 15 years of experience, contributing to unique market insights through extensive company research [3][4]. Group 2: Long-Term Performance - As of August 2025, Morgan Asset Management's active equity investment team has achieved an annualized return of 13.03% over the past 20 years, ranking in the top 10 of the industry [5][6]. - The "Double Ten" funds, which have been established for over 10 years and achieved annualized returns exceeding 10%, demonstrate strong resilience through various market cycles [6][18]. Group 3: Fund Performance Highlights - The Morgan Emerging Power Fund has an annualized return of 15.75% since its inception in 2011, while the Morgan China Advantage Fund has achieved a return of 13.51% since 2004 [7][9]. - The Morgan Core Growth Fund and Morgan Technology Frontier Fund have also shown significant returns, with annualized rates of 11.61% and 10.40%, respectively, showcasing the effectiveness of their investment strategies [11][12]. Group 4: Team Development and Global Perspective - Approximately 70% of Morgan Asset Management's equity fund managers are internally promoted, ensuring a cohesive team culture and deep market understanding [14]. - The firm leverages its global platform to access extensive research resources, integrating global insights with local market knowledge to enhance investment decision-making [14][16].

Group 1 - The core viewpoint of the article emphasizes the transition of the public fund industry from a "star model" to a "platform model," focusing on building a "platform-based, integrated, multi-strategy" investment research system [1] - Experienced fund managers with over ten years of management experience are showcasing unique value during this transition, as they have navigated multiple market cycles [1][2] - As of August 31, 2025, there are fewer than 100 fund managers in the public fund industry who have continuously managed the same active equity fund for over ten years, representing only about 5% of equity and mixed product fund managers [1][2] Group 2 - Fund managers with over 14 years of experience have demonstrated impressive performance, with annualized returns exceeding 10% for their representative funds [2] - Notable fund managers include Du Meng from Morgan Asset Management, with an annualized return of 15.7%, and others like Zhu Shaoxing and Li Wei, with returns of 15.4% and 14.8%, respectively [2] - The annualized return of the Shanghai Composite Index over the past 14 years is only 2%, indicating that experienced fund managers can generate substantial performance through long-term investment [2] Group 3 - Active investment has seen a significant performance rebound, with 30% of active stock and mixed funds achieving returns over 50% in the past year [3] - Fund managers with over ten years of experience have shown more stable performance, with Du Meng's managed funds yielding returns between 83% and 96% in the past year [3] Group 4 - Historical data indicates that longer holding periods lead to better investor returns, with a 93.2% positive return rate for holding equity funds for five years [4] Group 5 - The article highlights the importance of a supportive platform and culture for fund managers, with companies that have a deep understanding of equity investment fostering long-term management [8] - Morgan Asset Management has maintained a "long-distance" investment culture, with 80% of its global long-term funds outperforming the industry median over the past decade [8][9] Group 6 - The article concludes that the public fund industry is likely to see more fund managers who adhere to long-termism and leverage team intelligence and systematic methods, which is essential for high-quality development in the industry [9]

Group 1 - The core viewpoint highlights the strong performance of the innovative drug ETF (560900), which saw a more than 2% increase in intraday trading, with significant trading volume and a notable rise in the underlying index [1] - The innovative drug ETF (560900) has shown impressive growth, with a weekly increase leading among comparable funds, and a substantial rise in both scale and shares over the past three months and six months [1] - WuXi AppTec's half-year performance forecast indicates a revenue of approximately 20.8 billion yuan, a year-on-year growth of about 20.64%, and a net profit attributable to shareholders of around 8.6 billion yuan, reflecting a significant year-on-year increase of approximately 101.92% [1] Group 2 - The trend of Chinese innovative drugs going global is accelerating, with the total value of License-out transactions expected to exceed $43 billion in 2024, accounting for nearly 20% of the global market [2] - The current overseas expansion models include "building ships" (self-declaration for overseas listing) and "borrowing ships" (outsourcing or establishing NewCo), with successful examples like BeiGene's Zebrutinib and Legend Biotech's Cilta-cel [2] - The total value of outbound licensing transactions reached $51.9 billion in 2024, with $48.4 billion disclosed in the first half of 2025, indicating a robust growth trajectory for Chinese innovative drugs [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to assist investors in seizing investment opportunities in quality technology companies amid a new wave of technological advancements driven by AI [2] - Various actively managed funds focus on emerging industry trends, including the Morgan Emerging Power Fund, which aims to capture opportunities in new industries, and the Morgan Smart Connectivity Fund, which targets AI-related sectors [3] - Passive investment options include the Morgan Hang Seng Technology ETF and the Morgan China Innovation Drug Industry ETF, providing investors with easy access to technology and innovative drug sectors [3]

Core Viewpoint - The article discusses the evolving landscape of the Chinese equity market, highlighting a shift in global perception of Chinese assets and the potential for A-shares to catch up with the performance of Hong Kong stocks in the coming months to a year [3]. Group 1: Market Performance - Recent months have shown a recovery in the Chinese market, with A-shares and Hong Kong stocks rebounding quickly after initial shocks from tariff disputes [3]. - The Hang Seng Index has increased by 27.64% from September 24, 2024, to May 31, 2025, while the CSI 300 Index has risen by 19.53% during the same period, indicating a stronger performance in Hong Kong stocks compared to A-shares [3]. Group 2: Investment Focus Areas - Four key sectors are highlighted for future investment: AI, innovative pharmaceuticals, consumer goods, and power batteries [4][5]. - AI is seen as a core direction for global technological development, with significant investment opportunities in computing power and related hardware [4]. - The innovative pharmaceutical sector is expected to grow, driven by advancements in research and development within Chinese companies [7]. - The consumer sector is viewed as having no clear distinction between "new" and "old" consumption, with opportunities arising from cultural exports as China continues to grow as a super economy [4]. - The power battery sector remains promising due to its vast market potential across various applications, including energy storage and robotics [5]. Group 3: Healthcare Sector Insights - The innovative pharmaceutical market is anticipated to be a long-term trend, with China's pharmaceutical capabilities aligning with global standards [7]. - Investment opportunities are focused on companies in pharmaceuticals, medical devices, and high-value consumables, with a preference for firms with strong clinical and sales capabilities [7]. Group 4: Consumer Sector Dynamics - The future performance of the consumer sector is closely tied to domestic demand, which is influenced by residents' income expectations [9]. - Recent consumer subsidies in sectors like automotive and home appliances have created opportunities, and sustained policy support could further drive growth [10]. Group 5: Technology Sector Developments - The technology sector, particularly AI, is expected to play a crucial role in overcoming current economic challenges, with AI development projected to continue for decades [12]. - Investment opportunities are identified in smart driving and humanoid robots, with the latter expected to see production growth in specific industries [12]. Group 6: Manufacturing and Resource Insights - The manufacturing sector is poised for growth, with opportunities for Chinese brands to compete globally due to improved product performance and stability [16]. - Resource-related companies are also highlighted, as limited supply supports pricing and profitability [16]. Group 7: Financial Sector Outlook - The banking sector has shown resilience, with improved performance attributed to better-than-expected corporate conditions outside the real estate sector [18]. - As the economic outlook improves, expectations for the banking sector are also anticipated to recover [18]. Group 8: Consumer Goods Sector Analysis - The white liquor industry is undergoing adjustments primarily due to inventory cycles and operational challenges, with potential for recovery as internal adjustments take place [21].

Group 1 - The innovative drug ETF (560900) has seen a 1.14% increase as of July 4, 2025, with an active trading volume of 12.11% [1] - The CSI Innovative Drug Industry Index (931152) rose by 0.95%, with notable increases in constituent stocks such as Zhenjiang Cell (688520) up 19.31% and Rongchang Bio (688331) up 10.54% [1] - Over the past week, the innovative drug ETF (560900) has accumulated a 3.92% increase, reaching a six-month high in its latest scale [1] Group 2 - The National Healthcare Security Administration and the National Health Commission have jointly issued measures to support the high-quality development of innovative drugs, establishing a full-chain policy loop from R&D to payment [2] - The new policy includes the establishment of a commercial health insurance directory for innovative drugs, allowing for confidential pricing mechanisms and special policy treatments [2] - Jianghai Securities noted that the 2025 policy measures will further stimulate R&D efforts and accelerate the market entry of innovative drugs, marking a transition to the 2.0 phase of support policies [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to help investors capitalize on quality tech companies amid a new wave of technological advancements driven by AI [2] - Various actively managed funds focus on emerging industry trends, AI opportunities, and sectors like the new energy vehicle supply chain and humanoid robotics [3] - Passive investment options include the Morgan Hang Seng Technology ETF and the Morgan CSI Innovative Drug Industry ETF, providing easy access to tech assets and innovative drug companies in China [3]

Group 1 - The core viewpoint highlights the significant growth and performance of the innovative pharmaceutical ETF (560900), which has seen a 1.64% increase and is experiencing active trading with a turnover of 12.59% and a transaction volume of 4.4435 million yuan [1] - The CSI Innovative Pharmaceutical Industry Index (931152) has also shown strong performance, rising by 1.83%, with notable increases in constituent stocks such as Rongchang Bio (688331) up 10.28%, Zai Lab (688266) up 6.28%, and Yifan Pharmaceutical (002019) up 5.77% [1] - As of June 30, the innovative pharmaceutical ETF (560900) has seen a significant increase in shares by 500,000, ranking first among comparable funds [1] Group 2 - According to Guojin Securities, the global competitiveness of innovative drugs is becoming more prominent, with accelerated external licensing and a trend towards profitability in the industry [1] - The number and quality of new drug approvals in China have continued to improve since the beginning of 2025, with an increasing pace of commercialization for innovative drugs and the introduction of internationally leading new drugs into China [1] - The innovative pharmaceutical sector, which has experienced several years of stagnation, is now considered to be in a value trough [1] Group 3 - The rise of AI is driving a new wave of technological advancements, prompting Morgan Asset Management to integrate its "Global Vision Investment Technology" product line to assist investors in strategically positioning themselves in quality tech companies [1] - Morgan's actively managed funds focus on emerging industry trends, including the Morgan Emerging Power Fund and the Morgan Smart Connectivity Fund, which targets opportunities in artificial intelligence [2] - The passive investment options include the Morgan Hang Seng Technology ETF and the Morgan CSI Innovative Pharmaceutical Industry ETF, providing easy access to Chinese innovative pharmaceutical companies [2]